Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: Enriching structure-function studies and structure-activity relationships

Molecular Pharmacology

Volumn 82, Issue 5, 2012, Pages 860-875

  Gregory, Karen J ^a,c   Noetzel, Meredith J ^a   Rook, Jerri M ^a   Vinson, Paige N ^a   Stauffer, Shaun R ^a   Rodriguez, Alice L ^a   Emmitte, Kyle A ^a,b   Zhou, Ya ^a   Chun, Aspen C ^a   Felts, Andrew S ^a   Chauder, Brian A ^a   Lindsley, Craig W ^a,b   Niswender, Colleen M ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; METABOTROPIC RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEGATIVE ALLOSTERIC MODULATOR; POSITIVE ALLOSTERIC MODULATOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING SITE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CALCIUM; GLUTAMIC ACID; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POINT MUTATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867831749     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.080531     Document Type: Article

References (60)

1. 5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Bioorg Med Chem Lett 21:3243-3247.
2. 2+ signaling initiated by the type 5 metabotropic glutamate receptor. Mol Pharmacol 76:1302-1313.
3. Bradley SJ, Langmead CJ, Watson JM, and Challiss RA (2011) Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 79:874-885.
4. Chen Y, Goudet C, Pin JP, and Conn PJ (2008) N -{4-Chloro-2-[(1,3-dioxo- 1,3-dihydro-2 H -isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 73:909-918. (Pubitemid 351397895)
5. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, and Conn PJ (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol 71:1389-1398. (Pubitemid 46661543)
6. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Chua PC, Nagasawa JY, Bleicher LS, Munoz B, Schweiger EJ, Tehrani L, Anderson JJ, Cramer M, Chung J, Green MD, et al. (2005) Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett 15:4589-4593. (Pubitemid 41253900)
8. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13:351-354.
9. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, et al. (2003b) 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206. (Pubitemid 36078139)
10. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, and Christopoulos A (2012) Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology 153:1232-1241.
11. de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, and Conn PJ (2006) Substituent effects of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 49:3332-3344. (Pubitemid 43830531)
12. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
13. Emery AC, DiRaddo JO, Miller E, Hathaway HA, Pshenichkin S, Takoudjou GR, Grajkowska E, Yasuda RP, Wolfe BB, and Wroblewski JT (2012) Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling. Mol Pharmacol 82:291-301.
14. 5: identification of easily prepared tool compounds with CNS exposure in rats. Bioorg Med Chem Lett 20:4390-4394.
15. Felts AS, Saleh SA, Le U, Rodriguez AL, Weaver CD, Conn PJ, Lindsley CW, and Emmitte KA (2009) Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett 19:6623-6626.
16. Galambos J, Wágner G, Nógrádi K, Bielik A, Molnár L, Bobok A, Horváth A, Kiss B, Kolok S, Nagy J, et al. (2010) Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists. Bioorg Med Chem Lett 20:4371-4375.
17. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503. (Pubitemid 29457731)
18. Gilbert AM, Bursavich MG, Lombardi S, Adedoyin A, Dwyer JM, Hughes Z, Kern JC, Khawaja X, Rosenzweig-Lipson S, Moore WJ, et al. (2011) 3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies. Bioorg Med Chem Lett 21:195-199.
19. Gregory KJ, Sexton PM, and Christopoulos A (2010) Overview of receptor allosterism. Curr Protoc Pharmacol Unit 1.21.
20. 5 allosteric ligands with distinct modes of pharmacology. ACS Chem Neurosci 1:702-716.
21. Huang D, Poon SF, Chapman DF, Chung J, Cramer M, Reger TS, Roppe JR, Tehrani L, Cosford ND, and Smith ND (2004) 2-(2-[3-(Pyridin-3-yloxy)phenyl]-2H- tetrazol-5-yl)pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett 14:5473-5476. (Pubitemid 39346327)
22. Jaeschke G, Porter R, Büttelmann B, Ceccarelli SM, Guba W, Kuhn B, Kolczewski S, Huwyler J, Mutel V, Peters JU, et al. (2007) Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists. Bioorg Med Chem Lett 17:1307-1311. (Pubitemid 46240847)
23. Kawabata S, Tsutsumi R, Kohara A, Yamaguchi T, Nakanishi S, and Okada M (1996) Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors. Nature 383:89-92. (Pubitemid 26296467)
24. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
25. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206. (Pubitemid 40411343)
26. Kulkarni SS, Nightingale B, Dersch CM, Rothman RB, and Newman AH (2006) Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett 16:3371-3375. (Pubitemid 43792524)
27. Kulkarni SS, Zou MF, Cao J, Deschamps JR, Rodriguez AL, Conn PJ, and Newman AH (2009) Structure-activity relationships comparing N-(6-methylpyridin- yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. J Med Chem 52:3563-3575.
28. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
29. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389. (Pubitemid 47087967)
30. Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, et al. (2011) CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 339:474-486.
31. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, et al. (2008) ADX47273 [S-(4-fluoro-phenyl)- {3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 327:827-839.
32. Malherbe P, Kratochwil N, Mühlemann A, Zenner MT, Fischer C, Stahl M, Gerber PR, Jaeschke G, and Porter RH (2006) Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J Neurochem 98:601-615. (Pubitemid 44133162)
33. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, Fischer C, and Porter RH (2003) Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol Pharmacol 64:823-832. (Pubitemid 37153050)
34. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, and Lindsley CW (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55:1445-1464.
35. Milbank JB, Knauer CS, Augelli-Szafran CE, Sakkab-Tan AT, Lin KK, Yamagata K, Hoffman JK, Zhuang N, Thomas J, Galatsis P, et al. (2007) Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett 17:4415-4418. (Pubitemid 47058971)
36. 5): from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem 7:406-414.
37. Mühlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, Stucki A, Jaeschke G, Malherbe P, and Porter RH (2006) Determination of key amino acids implicated in the actions of allosteric modulation by 3,3′- difluorobenzaldazine on rat mGlu5 receptors. Eur J Pharmacol 529:95-104.
38. 3H]quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem 75:2590-2601.
39. 2+ and inositol 1,4,5-trisphosphate oscillation frequency: receptor density versus agonist concentration. J Biol Chem 277:35947-35960.
40. Niswender CM and Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322.
41. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, et al. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 81:120-133.
42. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577. (Pubitemid 38542609)
43. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezèau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1α-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
44. Poon SF, Eastman BW, Chapman DF, Chung J, Cramer M, Holtz G, Cosford ND, and Smith ND (2004) 3-[3-Fluoro-5-(5-pyridin-2-yl-2 H -tetrazol-2-yl)phenyl]-4- methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett 14:5477-5480. (Pubitemid 39346328)
45. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, et al. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105-1123.
46. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, and Conn PJ (2005) A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802. (Pubitemid 41654362)
47. 5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett 19:3209-3213.
48. Roppe J, Smith ND, Huang D, Tehrani L, Wang B, Anderson J, Brodkin J, Chung J, Jiang X, King C, et al. (2004) Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem 47:4645-4648. (Pubitemid 39195554)
49. 5 allosteric modulators: highly potent positive and negative modulators from one chemotype. Bioorg Med Chem Lett 21:3407-3410.
50. Tehrani LR, Smith ND, Huang D, Poon SF, Roppe JR, Seiders TJ, Chapman DF, Chung J, Cramer M, and Cosford ND (2005) 3-[Substituted]-5-(5-pyridin-2-yl-2H- tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists. Bioorg Med Chem Lett 15:5061-5064. (Pubitemid 41400185)
51. Thandi S, Blank JL, and Challiss RA (2002) Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 83:1139-1153. (Pubitemid 35397124)
52. Vanejevs M, Jatzke C, Renner S, Müller S, Hechenberger M, Bauer T, Klochkova A, Pyatkin I, Kazyulkin D, Aksenova E, et al. (2008) Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem 51:634-647. (Pubitemid 351252291)
53. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, et al. (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181. (Pubitemid 29302317)
54. 5 NAMs. Bioorg Med Chem Lett 20:3737-3741.
55. Weiss JM, Jimenez HN, Li G, April M, Uberti MA, Bacolod MD, Brodbeck RM, and Doller D (2011) 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett 21:4891-4899.
56. Wood MR, Hopkins CR, Brogan JT, Conn PJ, and Lindsley CW (2011) "Molecular switches" on mGlu allosteric ligands that modulate modes of pharmacology. Biochemistry 50:2403-2410.
57. Yang L, Mao L, Chen H, Catavsan M, Kozinn J, Arora A, Liu X, and Wang JQ (2006) A signaling mechanism from Gαq-protein-coupled metabotropic glutamate receptors to gene expression: role of the c-Jun N-terminal kinase pathway. J Neurosci 26:971-980. (Pubitemid 43237089)
58. Zhang P, Zou MF, Rodriguez AL, Conn PJ, and Newman AH (2010) Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5. Bioorg Med Chem 18:3026-3035.
59. 5 potentiators with improved in vivo utility. ACS Med Chem Lett 1:433-438.
60. Zou MF, Cao J, Rodriguez AL, Conn PJ, and Newman AH (2011) Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 21:2650-2654.